Chronic pain management, Digital Health and Pharmaceuticals

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Chronic pain management

Digital Health

Pharmaceuticals

Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain

Digital Health Global

JANUARY 29, 2024

As showcased in the ‘ VIRPI ‘ study, ODD-403 marks a statistically significant advancement in chronic pain management. Newel Health is well poised to leverage ODD-403’s compelling clinical findings, underscoring its commitment to delivering validated and impactful digital health solutions.

Pharmaceuticals

Pharmaceuticals Chronic pain management Digital Health Pain management

Average Multiples and Key Drivers of Digital Therapeutics (DTx) M&A deals in 2023

Lloyd Price

NOVEMBER 25, 2023

This is due to a number of factors, including: The increasing prevalence of chronic diseases The rising cost of healthcare The increasing demand for patient-centered care As a result, DTx companies are still expected to be attractive targets for M&A deals. The average deal size for DTx M&A deals is increasing. Subscribe Today!

Pharmaceuticals

Pharmaceuticals Pain management Chronic pain management Mental health

Connected Health Pulse

Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain

Average Multiples and Key Drivers of Digital Therapeutics (DTx) M&A deals in 2023

Stay Connected